indicating a significant difference. The values were expressed as the mean ± standard deviation. The analysis set consisted of 26 patients in total, with the initial drug being risperidone in 11 patients (the risperidone group), olanzapine in 8 patients (the olanzapine group) and blonanserin in 7 patients (the blonanserin group). The length of time from the start of antipsychotic drug treatment to the addition of valproic acid was 4.6 ± 2.8 weeks in the risperidone group, 4.4 ± 3.0 weeks in the olanzapine group, and 4.0 ± 2.9 weeks in the blonanserin group. Thus, valproic acid began to be used within 6 weeks after treatment initiation in more than half of all patients. The age and the dose level of the antipsychotic drug and valproic acid in each group were as follows. In the risperidone group, the age was 42.3 ± 12.9 years, the risperidone dose was 5.9 ± 3.4 mg and the valproic acid dose was 761 ± 375 mg. In the olanzapine group, the age was 38.3 ± 13.3 years, the olanzapine dose was 16.5 ± 5.3 mg and the valproic acid dose was 744 ± 359 mg. In the blonanserin group, the age was 40.8 ± 16.1 years, the blonanserin dose was 14.2 ± 9.8 mg and the valproic acid dose was 804 ± 304 mg. Figure 1 shows the change over time in the mean body weight in each group and Figure 2 shows the change over time in the mean non-HDL-C level. Weight gain during the antipsychotic monotherapy and during the valproic acid add-on therapy was 1.9 ± 0.8 kg and 2.2 ± 1.1 kg in the risperidone group, 7.0 ± 3.1 kg and 1.8 ± 0.8 kg in the olanzapine group and 0.6 ± 0.5 kg and 1.2 ± 0.9 kg in the blonanserin group, respectively. The magnitude of the increase in the non-HDL-C level during the antipsychotic monotherapy and during the valproic acid add-on 24 therapy was 9.8 ± 6.2 mg/dL and 12.4 ± 4.3 mg/dL in the risperidone group, 26.0 ± 7.3 mg/dL and 16.4 ± 6.4 mg/dL in the olanzapine group and -1.0 ± 1.8 mg/dL and 2.3 ± 2.1 mg/dL in the blonanserin group, respectively. In the risperidone group, significant weight gain was noted during the add-on valproic acid treatment period compared before treatment initiation. In the olanzapine group, significant weight gain was noted during both the antipsychotic monotherapy period and the valproic acid add-on treatment period compared to before treatment initiation. The blonanserin group exhibited no significant weight gain. The non-HDL-C level increased significantly during the valproic acid add-on treatment period compared to before treatment initiation in the risperidone group. In the olanzapine group, the non-HDL-C level increased significantly during the antipsychotic monotherapy period and the valproic acid add-on treatment period compared to before treatment initiation, and the level was significantly higher during the valproic acid add-on treatment period than during the antipsychotic monotherapy period. No significant increase in the non-HDL-C level was noted in the blonanserin group. Valproic acid augmentation was associated with higher body weight as well as elevated non-HDL-C levels in the olanzapine and risperidone groups but not in the blonanserin group. These results indicate that both some atypical antipsychotic drugs and valproic acid are associated with a risk of metabolic disorders. It seems desirable to analyze the risk stemming from the combined use of these drugs because the mechanism through which valproic acid may induce weight gain is still debated. The limitations of the present study are that it was retrospectively conducted and the sample size was very small. The association between valproic acid add-on therapy and metabolic abnormalities, as evidenced by, for example, measurement of fasting blood glucose, insulin level and HbA1c, needs to be studied prospectively. 
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